Fagron N.V. (FAGR.BR)
Fagron N.V. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Nazareth, VL, BE. The stock last traded at $22.20, down 1.11% on the session, giving a market capitalisation of $1.63B. Its beta of 0.38 implies it has historically moved less than the broad market.
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
Fagron N.V. is most often compared with the following Healthcare names: